title: Biopsies in the Community Lead to Postoperative Complications in Soft Tissue Sarcomas.
abstract: Percutaneous biopsies allow for precise diagnosis in soft tissue sarcomas and have a low rate of complications. However, it is unknown whether biopsies performed in a community setting lead to higher rates of wound complications at the time of resection. The goal of this study was to determine whether percutaneous biopsies performed at a sarcoma center have lower rates of wound complications compared with those performed in the community setting. A total of 125 patients with soft tissue sarcomas were treated with neoadjuvant radiation followed by limb-sparing resection. Of these, 92 underwent percutaneous biopsy. Patient, demographic, and treatment variables and postoperative wound complications were reviewed. Predictors of wound complications were evaluated with Fisher's exact test for univariate analysis and with logistic regression for multivariate analysis. The wound complication rate was 27% for open or percutaneous biopsies. When only percutaneous biopsies were assessed, the wound complication rate was 25%. The wound complication rate for percutaneous biopsies was 18% when the biopsy was performed at the authors' sarcoma center and 46% when the biopsy was performed in the community setting (P=.01). The Common Terminology Criteria for Adverse Events grade 4 wound complication rate was 73% in patients who underwent percutaneous biopsy at a community hospital vs 14% in those who underwent percutaneous biopsy at the authors' sarcoma center (P=.005). Multivariate analysis showed that lower-extremity soft tissue sarcomas (P=.03) and biopsies performed in the community setting (P=.01) had an increased rate of postoperative wound complications. Percutaneous biopsies performed at community hospitals had an increased incidence of grade 4 postoperative wound toxicity compared with biopsies done at tertiary centers. These wound results confirmed previous recommendations that biopsy of soft tissue sarcomas should be performed at an experienced sarcoma center.
authors.forename: Meena
authors.initials: M
authors.lastname: Bedi
authors.forename: David M
authors.initials: DM
authors.lastname: King
authors.forename: Donald A
authors.initials: DA
authors.lastname: Hackbarth
authors.forename: John A
authors.initials: JA
authors.lastname: Charlson
authors.forename: Keith
authors.initials: K
authors.lastname: Baynes
authors.forename: John C
authors.initials: JC
authors.lastname: Neilson
mesh_terms: D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D002173:Cancer Care Facilities; D005121:Extremities; D005260:Female; D006801:Humans; D061705:Image-Guided Biopsy / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020360:Neoadjuvant Therapy; D009379:Neoplasms, Muscle Tissue / Q000473:pathology* / Q000601:surgery; D059351:Organ Sparing Treatments; D011183:Postoperative Complications / Q000209:etiology* / Q000473:pathology; D018714:Radiotherapy, Adjuvant; D012509:Sarcoma / Q000473:pathology* / Q000601:surgery; D016896:Treatment Outcome